{"nctId":"NCT04332991","briefTitle":"Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","startDateStruct":{"date":"2020-04-02","type":"ACTUAL"},"conditions":["Coronavirus","Acute Respiratory Infection","SARS-CoV Infection"],"count":479,"armGroups":[{"label":"Hydroxychlorquine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Hydroxychloroquine"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Hydroxychloroquine","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years\n2. Currently hospitalized or in an emergency department with anticipated hospitalization.\n3. Symptoms of acute respiratory infection, defined as one or more of the following:\n\n   1. cough\n   2. fever (\\> 37.5° C / 99.5° F)\n   3. shortness of breath (operationalized as any of the following: subjective shortness of breath reported by patient or surrogate; tachypnea with respiratory rate ≥22 /minute; hypoxemia, defined as SpO2 \\<92% on room air, new receipt of supplemental oxygen to maintain SpO2 ≥92%, or increased supplemental oxygen to maintain SpO2 ≥92% for a patient on chronic oxygen therapy).\n   4. sore throat\n4. Laboratory-confirmed SARS-CoV-2 infection within the past 10 days prior to randomization.\n\nExclusion Criteria:\n\n1. Prisoner\n2. Pregnancy\n3. Breast feeding\n4. Symptoms of acute respiratory infection for \\>10 days before randomization\n5. \\>48 hours between meeting inclusion criteria and randomization\n6. Seizure disorder\n7. Porphyria cutanea tarda\n8. Diagnosis of Long QT syndrome\n9. QTc \\>500 ms on electrocardiogram within 72 hours prior to enrollment\n10. Known allergy to hydroxychloroquine, chloroquine, or amodiaquine\n11. Receipt in the 12 hours prior to enrollment, or planned administration during the 5-day study period that treating clinicians feel cannot be substituted for another medication, of any of the following: amiodarone; cimetidine; dofetilide; phenobarbital; phenytoin; sotalol\n12. Receipt of \\>1 dose of hydroxychloroquine or chloroquine in the 10 days prior to enrollment\n13. Inability to receive enteral medications\n14. Refusal or inability to be contacted on Day 15 for clinical outcome assessment if discharged prior to day 15\n15. Previous enrollment in this trial\n16. The treating clinical team does not believe equipoise exists regarding the use of hydroxychloroquine for the treatment of this patient","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"COVID Outcomes Scale Score on Study Day 15 (14 Days After Randomization)","description":"We will determine the COVID Ordinal Scale for all patients on study day 15\n\nCOVID Ordinal Scale defined as:\n\n1. Death\n2. Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)\n3. Hospitalized on non-invasive ventilation or high flow nasal cannula\n4. Hospitalized on supplemental oxygen\n5. Hospitalized not on supplemental oxygen\n6. Not hospitalized with limitation in activity (continued symptoms)\n7. Not hospitalized without limitation in activity (no symptoms)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID Ordinal Outcomes Scale on Study Day 3 (2 Days After Randomization)","description":"We will determine the COVID Ordinal Scale for all patients on study day 3\n\nCOVID Ordinal Scale defined as:\n\n1. Death\n2. Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)\n3. Hospitalized on non-invasive ventilation or high flow nasal cannula\n4. Hospitalized on supplemental oxygen\n5. Hospitalized not on supplemental oxygen\n6. Not hospitalized with limitation in activity (continued symptoms)\n7. Not hospitalized without limitation in activity (no symptoms)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID Ordinal Outcomes Scale on Study Day 8 (7 Days After Randomization)","description":"We will determine the COVID Ordinal Scale on study day 8\n\nCOVID Ordinal Scale defined as:\n\n1. Death\n2. Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)\n3. Hospitalized on non-invasive ventilation or high flow nasal cannula\n4. Hospitalized on supplemental oxygen\n5. Hospitalized not on supplemental oxygen\n6. Not hospitalized with limitation in activity (continued symptoms)\n7. Not hospitalized without limitation in activity (no symptoms)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"COVID Ordinal Outcomes Scale on Study Day 29 (28 Days After Randomization)","description":"We will determine the COVID Ordinal Scale on study day 29\n\nCOVID Ordinal Scale defined as:\n\n1. Death\n2. Hospitalized on invasive mechanical ventilation or ECMO ( extracorporeal membrane oxygenation)\n3. Hospitalized on non-invasive ventilation or high flow nasal cannula\n4. Hospitalized on supplemental oxygen\n5. Hospitalized not on supplemental oxygen\n6. Not hospitalized with limitation in activity (continued symptoms)\n7. Not hospitalized without limitation in activity (no symptoms)","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"All-location, All-cause Mortality Assessed on Study Day 15 (14 Days After Randomization)","description":"Vital status of the patient on day 15 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.\n\nThere were two patients for whom we were unable to collect their vital status.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"All-location, All-cause Mortality Assessed on Study Day 29 (28 Days After Randomization)","description":"Vital status of the patient at day 28 will be determined using any of the following methods: medical record review, phone calls to patient or proxy.\n\nThere were two patients for whom we were unable to collect their vital status.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Dead or With Receipt of ECMO Between Enrollment and Day 28","description":"We will determine the number of patients who are either dead or on ECMO ( extracorporeal membrane oxygenation) between enrollment and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Oxygen-free Days Through Day 28","description":"The number of calendar days between randomization and 28 days later that the patient is alive and without the use of oxygen therapy. Patients who die prior to day 28 are assigned zero oxygen free days.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Ventilator-free Days Through Day 28","description":"Ventilator-free days is defined to be 28 days minus the duration of mechanical ventilation through day 28. Participants who do not survive to day 28 are assigned zero ventilator-free days.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Vasopressor-free Days Through Day 28","description":"The number of calendar days between randomization and 28 days later that the patient is alive and without the use of vasopressor therapy. Patients who die prior to day 28 are assigned zero vasopressor free days.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"ICU-free Days to Day 28","description":"The number of days spent out of the ICU to day 28. Patients who die prior to day 28 are assigned zero ICU free days.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital-free Days to Day 28","description":"Defined as 28 days minus the number of days from randomization to discharge home.If a patient has not been discharged home prior to day 28 or dies prior to day 28, hospital free days will be zero.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Seizures to Day 28","description":"We will determine the number of patients that experience seizure between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Atrial Arrhythmia to Day 28","description":"We will determine the number of patients that experience atrial arrhythmia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Ventricular Arrhythmia to Day 28","description":"We will determine the number of patients that experience ventricular arrhythmia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Cardiac Arrest to Day 28","description":"We will determine the number of patients that experience cardiac arrest between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Elevation in Aspartate Aminotransferase or Alanine Aminotransferase to Twice the Local Upper Limit of Normal to Day 28","description":"We will determine the number of patients that experience elevation in aspartate aminotransferase or alanine aminotransferase to twice the local upper limit of normal between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Acute Pancreatitis Arrest to Day 28","description":"We will determine the number of patients that experience acute pancreatitis between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Acute Kidney Injury to day28","description":"We will determine the number of patients that experience acute kidney injury between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Receipt of Renal Replacement Therapy to Day 28","description":"We will determine the number of patients that experience renal replacement therapy between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Symptomatic Hypoglycemia to Day 28","description":"We will determine the number of patients that experience symptomatic hypoglycemia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Neutropenia to Day 28","description":"We will determine the number of patients that experience neutropenia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Lymphopenia to Day 28","description":"We will determine the number of patients that experience lymphopenia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"87","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Anemia to Day 28","description":"We will determine the number of patients that experience anemia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"120","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Thrombocytopenia to Day 28","description":"We will determine the number of patients that experience thrombocytopenia between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Patients With Severe Dermatologic Reaction to Day 28","description":"We will determine the number of patients that experience severe dermatologic reaction between randomization and day 28","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Time to Recovery, Defined as Time to Reaching Level 5, 6, or 7 on the COVID Outcomes Scale, Which is the Time to the Earlier of Final Liberation From Supplemental Oxygen or Hospital Discharge","description":"Time to recovery, defined as time to reaching level 5, 6, or 7 on the COVID Outcomes Scale, which is the time to the earlier of final liberation from supplemental oxygen or hospital discharge. Patients who die prior to day 28 are assigned 28 days for time to recovery.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":242},"commonTop":["Multiple Liver Function Tests Abnormal","Prolonged QTc","Headache","Atrial Arrythmia","Nausea"]}}}